Partnerships
Gilead Sciences Partners With Vir Biotechnology on Three Solid-Tumor Drugs in Deal Worth Up to $1.74 Billion
By News Desk ·
Key takeaways
- Gilead Sciences partnered with Vir Biotechnology on October 14, 2026 to discover and develop three drugs aimed at solid tumors.
- Vir Biotechnology is eligible for $90 million upfront, up to $45 million in near-term preclinical milestones and as much as $1.74 billion in later payments.
- Vir will handle early discovery using its AI-enabled protein engineering tools and PRO-XTEN masking technology, while Gilead leads development, manufacturing and commercialization.
Gilead Sciences partnered with Vir Biotechnology on October 14, 2026 to discover and develop three drugs aimed at solid tumors, a deal worth up to $1.74 billion in later payments. TradingView reported the agreement, which gives Gilead exclusive rights to nominate candidates.
How the Gilead and Vir Biotechnology Deal Works
Under the agreement, Vir Biotechnology will handle early discovery, design and optimization using its AI-enabled protein engineering tools and PRO-XTEN masking technology. Gilead receives exclusive rights to nominate candidates and will lead subsequent development, manufacturing and commercialization. Vir is eligible for $90 million upfront, made up of $65 million in cash plus a $25 million equity investment at a premium, plus up to $45 million in near-term preclinical milestones and as much as $1.74 billion in later development, regulatory and commercial payments, along with tiered royalties.
The agreement marks Vir's second major partnership around its masking platform this year, after a previous deal with Astellas, and adds to Gilead's attempts to advance its cancer offerings besides its blockbuster drug Trodelvy. Vir Biotechnology announced the collaboration and license agreement with Gilead to develop three novel PRO-XTEN dual-masked T-cell engagers for solid tumors, Stock Titan reported.
Gilead's Oncology and HIV Approvals on Record
Gilead Sciences develops and commercializes more than 25 medicines across virology, oncology and inflammation therapeutic areas, according to akta.pro company records. The same records show the FDA approved Trodelvy for first-line metastatic triple-negative breast cancer as monotherapy and in combination with Keytruda in June 2026, expanding the oncology franchise into the PD-L1+ front-line setting. In May 2026, the FDA granted accelerated approval to Hepcludex, making it the first and only approved treatment for chronic hepatitis delta virus infection in the United States.
Gilead's Recent Partnership Run
Gilead Sciences and Nurix Therapeutics extended the research term for an undisclosed oncology program by two years in October 2026, with Nurix receiving a $10 million fee, Stock Titan reported. Cognizant announced a five-year extension of its work with Gilead Sciences in October 2026, supporting DevOps capabilities and agentic AI tools across selected technology programs, PR Newswire reported. Gilead Sciences will release its third-quarter 2026 financial results and guidance after market close on October 29, 2026, Stock Titan reported.
What Comes Next for Gilead
Gilead Sciences will release its third-quarter 2026 financial results and guidance after market close on October 29, 2026, with management hosting a webcast at 4:30 p.m. Eastern Time. Vir Biotechnology will present Phase 2 SOLSTICE data on elebsiran and tobevibart for chronic hepatitis delta at AASLD The Liver Meeting 2026 in Denver, November 5-9, 2026, Stock Titan reported.